Induction sintilimab and chemotherapy followed by concurrent chemoradiotherapy for locally advanced esophageal cancer: a proof-of-concept, single-arm, multicenter, phase 2 trial
Authors:
Open Access
- 6 February 2024
- journal article
- research article
- Published by Elsevier in eClinicalMedicine
- Vol. 69, 102471
Abstract
No abstract availableKeywords
Funding Information
- Shanghai Rising-Star Program (23YF1406700)
- National Natural Science Foundation of China (82003033)
- National Natural Science Foundation of China (81872454)
- National Natural Science Foundation of China (U22A20326)
This publication has 29 references indexed in Scilit:
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung CancerNew England Journal of Medicine, 2017
- Tumor angiogenesis and vascular normalization: alternative therapeutic targetsAngiogenesis, 2017
- Mutual regulation of tumour vessel normalization and immunostimulatory reprogrammingNature, 2017
- Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating HypoxiaCancer Cell, 2014
- Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trialThe Lancet Oncology, 2013
- The Flow–Metabolic Phenotype of Primary Colorectal Cancer: Assessment by Integrated 18F-FDG PET/Perfusion CT with Histopathologic CorrelationJournal of Nuclear Medicine, 2012
- INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III Trial of Combined-Modality Therapy for Esophageal Cancer: High-Dose Versus Standard-Dose Radiation TherapyJournal of Clinical Oncology, 2002
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002
- Chemoradiotherapy of Locally Advanced Esophageal CancerJAMA, 1999
- Combined Chemotherapy and Radiotherapy Compared with Radiotherapy Alone in Patients with Cancer of the EsophagusNew England Journal of Medicine, 1992